Correction: Jacobs et al. Breast Cancer Research (2024) 26:69.
Following the publication of the original article, there were several errors, as follows:
In the abstract, Results section, “95% CI” should be included in the sixth sentence. It should read: “Molecular Response scores were significantly associated with both PFS (HR 0.28, 95% CI 0.09-0.90, P = 0.033) and best response (P = 0.037).”
On page 4, left-hand column: The word “samples,” after the word “two,” was mistakenly removed during typesetting. The correct statement should have been “ … the percent ctDNA change between the two timepoints based on the mean variant allele frequency (VAF) between two samples (mean VAF2/mean VAF1) -1 ? 100%.”
On page 7, left-hand column, a statement of “0.09-0.90, P = 0.033 using Wilcox test” was duplicated and has been removed.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher‘s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s13058-024-01823-8.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Jacobs, S.A., Wang, Y., Abraham, J. et al. Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer. Breast Cancer Res 26, 83 (2024). https://doi.org/10.1186/s13058-024-01833-6
Published:
DOI: https://doi.org/10.1186/s13058-024-01833-6